On May 28, 2024, Conduit Pharmaceuticals Inc. received a notice from The Nasdaq Stock Market LLC indicating that the company is not in compliance with Nasdaq's independent audit committee requirements. This non-compliance occurred following the resignation of Ms. Jennifer McNealey from the Board and all committees, leaving the audit committee with only two independent directors. The company has been given until the earlier of its next annual shareholders' meeting or May 13, 2025, to regain compliance, with an extended deadline of November 12, 2024, if the annual meeting occurs before that date. The notice does not affect the current listing of the company's securities on Nasdaq. Conduit Pharmaceuticals plans to address the issue by appointing at least one more independent director to the audit committee within the given timeframe.

On May 28, 2024, Conduit Pharmaceuticals Inc. received a notice from The Nasdaq Stock Market LLC indicating that the company is not in compliance with Nasdaq's independent audit committee requirements. This non-compliance occurred following the resignation of Ms. Jennifer McNealey from the Board and all committees, leaving the audit committee with only two independent directors. The company has been given until the earlier of its next annual shareholders' meeting or May 13, 2025, to regain compliance, with an extended deadline of November 12, 2024, if the annual meeting occurs before that date. The notice does not affect the current listing of the company's securities on Nasdaq. Conduit Pharmaceuticals plans to address the issue by appointing at least one more independent director to the audit committee within the given timeframe.